share_log

Zhi Tian Lai Spends CN¥6.0m On Zhongzhi Pharmaceutical Holdings Stock

Zhi Tian Lai Spends CN¥6.0m On Zhongzhi Pharmaceutical Holdings Stock

智天来花费600万元购买中智药业控股股票
Simply Wall St ·  04/25 07:54

Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) shareholders (or potential shareholders) will be happy to see that the Chairman, Zhi Tian Lai, recently bought a whopping HK$6.0m worth of stock, at a price of HK$1.20. There's no denying a buy of that magnitude suggests conviction in a brighter future, although we do note that proportionally it only increased their holding by 1.0%.

中智药业控股有限公司(HKG: 3737)的股东(或潜在股东)将很高兴看到主席赖智天最近以1.20港元的价格购买了价值高达60万港元的股票。不可否认,如此大规模的买入表明他们对更光明的未来充满信心,尽管我们确实注意到,按比例计算,这仅使他们的持股量增加了1.0%。

The Last 12 Months Of Insider Transactions At Zhongzhi Pharmaceutical Holdings

中智药业控股最近12个月的内幕交易

Notably, that recent purchase by Zhi Tian Lai is the biggest insider purchase of Zhongzhi Pharmaceutical Holdings shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of HK$1.22. Of course they may have changed their mind. But this suggests they are optimistic. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. Happily, the Zhongzhi Pharmaceutical Holdings insider decided to buy shares at close to current prices. Zhi Tian Lai was the only individual insider to buy during the last year.

值得注意的是,智天来最近的一次收购是我们去年对中智药业控股股票的最大一次内幕收购。这意味着内部人士乐于以当前1.22港元左右的价格购买股票。当然,他们可能改变了主意。但这表明他们很乐观。我们一直希望看到内幕买盘,但值得注意的是,这些收购的价格是否远低于今天的股价,因为随着价格的上涨,价值折扣可能已经缩小。令人高兴的是,中智药业控股内部人士决定以接近当前的价格购买股票。Zhi Tian Lai是去年唯一买入的内部人士。

Zhi Tian Lai bought a total of 29.87m shares over the year at an average price of HK$1.21. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

智天来全年共购买了2987万股股票,平均价格为1.21港元。下图显示了去年的内幕交易(公司和个人)。如果你点击图表,你可以看到所有的个人交易,包括股价、个人和日期!

insider-trading-volume
SEHK:3737 Insider Trading Volume April 24th 2024
SEHK: 3737 内幕交易量 2024 年 4 月 24 日

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

内部人士总是会买入很多股票。因此,如果这适合你的风格,你可以逐一查看每只股票,也可以看看这份免费的公司名单。(提示:业内人士一直在购买它们)。

Insider Ownership

内部所有权

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It's great to see that Zhongzhi Pharmaceutical Holdings insiders own 66% of the company, worth about HK$694m. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

许多投资者喜欢查看公司内部人士拥有多少股份。我们通常希望看到相当高的内部所有权。很高兴看到中智药业控股内部人士拥有该公司66%的股份,价值约6.94亿港元。大多数股东会很高兴看到这种内部所有权,因为这表明管理层的激励措施与其他股东非常一致。

So What Does This Data Suggest About Zhongzhi Pharmaceutical Holdings Insiders?

那么,这些数据对中智药业控股内部人士有何启示呢?

It is good to see the recent insider purchase. And the longer term insider transactions also give us confidence. When combined with notable insider ownership, these factors suggest Zhongzhi Pharmaceutical Holdings insiders are well aligned, and quite possibly think the share price is too low. Looks promising! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Zhongzhi Pharmaceutical Holdings. For example, Zhongzhi Pharmaceutical Holdings has 2 warning signs (and 1 which is concerning) we think you should know about.

很高兴看到最近的内幕收购。长期的内幕交易也给了我们信心。再加上显著的内部所有权,这些因素表明中智药业控股内部人士意见一致,很可能认为股价过低。看起来很有希望!除了了解正在进行的内幕交易外,确定中智药业控股面临的风险也是有益的。例如,中智药业控股有两个警告信号(其中一个令人担忧),我们认为你应该知道。

Of course Zhongzhi Pharmaceutical Holdings may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

当然,中智药业控股可能不是最好的买入股票。因此,您可能希望看到这个免费的高质量公司集合。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发